Mycomycen (Ciclopirox)

Ciclopirox disrupts fungal cell membranes by chelating iron and inhibiting sterol 14‑α‑demethylase, which blocks ergosterol synthesis. This impairs membrane integrity, leading to leakage of cellular contents and ultimately fungal cell death, providing broad‑spectrum activity against dermatophytes, yeasts and some molds.

The specific dosage and duration are determined by the prescribing healthcare professional based on the infection type, severity and patient factors. Typically, a thin layer is applied to the affected area once or twice daily for the period recommended by the prescriber.

Safety data for ciclopirox in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Mycomycen.

To place an order, submit an enquiry on the Mycomycen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mycomycen (ciclopirox) offers a broad spectrum of activity and works by inhibiting sterol synthesis, whereas terbinafine primarily targets the squalene epoxidase pathway. Both are effective for dermatophyte infections, but ciclopirox may be preferred for patients who experience irritation with allylamine agents or when a different mechanism of action is desired.

Store Mycomycen at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat and direct sunlight to maintain stability and potency.

Clean and dry the affected skin area before use. Apply a thin layer of Mycomycen to the lesion and a small margin of surrounding skin, gently rubbing it in. Follow the prescriber’s instructions regarding frequency, typically once or twice daily, and continue treatment for the full prescribed course even if symptoms improve.

While most reactions are mild, serious adverse events can include allergic contact dermatitis, severe skin rash, urticaria, extensive swelling or blistering, and very rare anaphylactic responses. Patients should discontinue use and seek immediate medical attention if they experience any signs of a severe allergic reaction.

Mycomycen should be avoided by individuals with a known hypersensitivity to ciclopirox or any other component of the formulation. It is also not recommended for use on extensive broken skin, mucous membranes, or in patients where a healthcare professional determines that the risks outweigh the benefits.